Emma K Link

Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast

I. Kunkler, J. Maduro, I. Olivotto, 2022 .

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non‐clear‐cell renal cell carcinoma

C. Gedye, G. Kichenadasse, H. Gurney, 2023, BJU international.